| Primary |
| Pruritus |
23.1% |
| Foetal Exposure During Pregnancy |
19.2% |
| Eczema |
15.4% |
| Product Used For Unknown Indication |
11.5% |
| Psoriasis |
7.7% |
| Rash |
7.7% |
| Sciatica |
7.7% |
| Dermatitis Atopic |
3.8% |
| Hepatitis C |
3.8% |
|
| Maternal Exposure During Pregnancy |
11.8% |
| Rash |
11.8% |
| Drug Exposure During Pregnancy |
5.9% |
| Eczema |
5.9% |
| Herpes Zoster |
5.9% |
| International Normalised Ratio Increased |
5.9% |
| Maternal Drugs Affecting Foetus |
5.9% |
| Pruritus |
5.9% |
| Renal Failure Acute |
5.9% |
| Scab |
5.9% |
| Sleep Disorder |
5.9% |
| Tinnitus |
5.9% |
| Visual Acuity Reduced |
5.9% |
| Visual Impairment |
5.9% |
| Wrong Drug Administered |
5.9% |
|
| Secondary |
| Product Used For Unknown Indication |
17.7% |
| Eczema |
11.4% |
| Rash |
11.4% |
| Acute Coronary Syndrome |
7.6% |
| Sciatica |
5.1% |
| Seborrhoeic Dermatitis |
5.1% |
| Asthenia |
3.8% |
| Asthma |
3.8% |
| Constipation |
3.8% |
| Dermatitis |
3.8% |
| Infection |
3.8% |
| Angina Pectoris |
2.5% |
| Cardiovascular Event Prophylaxis |
2.5% |
| Cerebral Infarction |
2.5% |
| Gastritis |
2.5% |
| Gastritis Prophylaxis |
2.5% |
| Hyperlipidaemia |
2.5% |
| Hypertension |
2.5% |
| Infantile Asthma |
2.5% |
| Neuralgia |
2.5% |
|
| Vasculitis |
18.2% |
| Congenital Genitourinary Abnormality |
13.6% |
| International Normalised Ratio Increased |
9.1% |
| Skin Test Positive |
9.1% |
| Visual Acuity Reduced |
9.1% |
| Acute Myocardial Infarction |
4.5% |
| Dermatitis Bullous |
4.5% |
| Off Label Use |
4.5% |
| Platelet Count Decreased |
4.5% |
| Rash Papular |
4.5% |
| Therapy Cessation |
4.5% |
| Thrombocytopenia |
4.5% |
| Ventricular Fibrillation |
4.5% |
| White Blood Cell Count Decreased |
4.5% |
|
| Concomitant |
| Psoriasis |
14.7% |
| Prophylaxis |
13.1% |
| Product Used For Unknown Indication |
11.1% |
| Colorectal Cancer |
9.5% |
| Hypertension |
7.6% |
| Hepatitis C |
5.8% |
| Dermatitis Atopic |
5.5% |
| Rash |
5.3% |
| Asthma |
3.5% |
| Chronic Hepatitis C |
3.3% |
| Eczema |
2.6% |
| Drug Use For Unknown Indication |
2.6% |
| Stomatitis |
2.4% |
| Gastritis |
2.2% |
| Rheumatoid Arthritis |
2.0% |
| Diabetes Mellitus |
1.9% |
| Tinea Infection |
1.7% |
| Diarrhoea |
1.7% |
| Insomnia |
1.7% |
| Acne |
1.6% |
|
| Rash |
11.7% |
| Vomiting |
9.1% |
| Decreased Appetite |
5.8% |
| Hepatic Function Abnormal |
5.8% |
| Pemphigoid |
5.2% |
| Stomatitis |
5.2% |
| White Blood Cell Count Decreased |
5.2% |
| White Blood Cell Count Increased |
5.2% |
| Dermatitis Acneiform |
4.5% |
| Toxic Skin Eruption |
4.5% |
| Cerebral Infarction |
3.9% |
| Cervix Carcinoma Stage 0 |
3.9% |
| Diarrhoea |
3.9% |
| Drug Eruption |
3.9% |
| Hepatic Neoplasm Malignant |
3.9% |
| Paronychia |
3.9% |
| Pyrexia |
3.9% |
| Syncope |
3.9% |
| Dry Skin |
3.2% |
| Oedema Peripheral |
3.2% |
|
| Interacting |
| Product Used For Unknown Indication |
40.0% |
| Psoriasis |
40.0% |
| Eczema |
20.0% |
|
| International Normalised Ratio Increased |
100.0% |
|
